Pain Therapeutics Inc. a biopharmaceutical company, today announced the issuance of four patents by the U.S. Patent and Trademark Office covering REMOXY (oxycodone) Extended-Release Capsules CII. These patents are the result of joint inventive work by scientists from both Pain Therapeutics and Durect Corporation. The four issued patents are licensed exclusively to Pain Therapeutics in the United States and international markets with regards to four opioid drugs.
"We believe these four issued patents can provide additional intellectual property protection for REMOXY until 2025 or beyond," said Remi Barbier, President and CEO of Pain Therapeutics.
The four recently issued patents are U.S. Patents 8,133,507; 8,168,217; 8,153,152 and 8,147,870. In Europe, REMOXY is covered by two granted patents that expire in 2016 and 2023, respectively, plus any eligible patent term extensions.
In 2005, Pain Therapeutics granted King Pharmaceuticals, Inc., now owned by Pfizer, Inc., (NYSE:PFE) exclusive, worldwide rights to REMOXY and three other proprietary pain medications. Pfizer has full control of the development and funding of REMOXY.
Source: Pain Therapeutics Inc.